A Biotech Turns Its Failed Trial Into an AI Model
A failed trial costs hundreds of millions and usually ends up shelved for good. This biotech instead reused the trial data to train a predictive model, which changes what a pharma failure can actually be worth. Whether other labs follow suit or this stays a one-off is still an open question.
practitioners › STAT News does not name the biotech or the model: worth watching once the full paper comes out.
STAT News →